Physician profile
Pushpendu Banerjee
NPI 1164497855
$29,025.64
in general payments reported to CMS, 2019-2025
69 companies · $4,908 in 2025
The $4,908 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $1,748 · 2021: $747 · 2022: $965 · 2023: $2,272 · 2024: $2,238 · 2025: $4,908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,946 · Consulting Fee: $2,000 · Travel and Lodging: $267 · Education: $207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,945.60 |
| Consulting Fee | $2,000.00 |
| Travel and Lodging | $266.90 |
| Education | $206.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Institutional INC. | $6,149.75 | 2019 | |
| Amag Pharmaceuticals, INC. | $5,027.27 | 2019 | |
| Astellas Pharma US INC | $2,723.25 | 2019-2025 | Vyloy, Xospata, Xtandi |
| Heron Therapeutics, INC. | $2,723.01 | 2019 | |
| Athenex Pharmaceutical Division, LLC | $1,250.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $998.07 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Astrazeneca Pharmaceuticals Lp | $824.54 | 2019-2025 | Imfinzi, Calquence |
| Novartis Pharmaceuticals Corporation | $729.33 | 2019-2025 | |
| Celgene Corporation | $573.84 | 2019-2025 | Reblozyl, Pomalyst, Onureg |
| Ipsen Biopharmaceuticals, INC | $572.89 | 2019-2024 | Tazverik, Onivyde, Somatuline Depot |
| Genzyme Corporation | $568.57 | 2019-2025 | |
| Pfizer INC. | $497.70 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $482.44 | 2021-2025 | Ultomiris |
| Janssen Biotech, INC. | $424.05 | 2019-2025 | Erleada, Carvykti, Darzalex |
| Merck Sharp & Dohme LLC | $350.15 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $317.55 | 2019 | |
| Amgen INC. | $302.39 | 2019-2023 | Kyprolis |
| Exelixis INC. | $280.76 | 2019-2025 | Cabometyx |
| Abbvie INC. | $276.44 | 2019-2025 | |
| Cardinal Health 108 LLC | $253.56 | 2019 | |
| Daiichi Sankyo INC. | $236.18 | 2020-2025 | Enhertu, Vanflyta |
| Blueprint Medicines Corporation | $213.67 | 2020-2024 | Ayvakit |
| Emd Serono, INC. | $183.46 | 2019-2024 | |
| Beigene USA, INC. | $173.16 | 2020-2024 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $173.01 | 2019-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $169.08 | 2019-2023 | Imbruvica |
| Gilead Sciences, INC. | $162.33 | 2021-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $156.95 | 2023-2025 | Libtayo |
| Genmab U.S., INC. | $150.00 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.41 | 2019-2025 | |
| Servier Pharmaceuticals LLC | $133.06 | 2021-2023 | |
| Verity Pharmaceuticals INC. | $128.67 | 2023-2025 | Trelstar |
| Lilly USA, LLC | $123.07 | 2021-2024 | Verzenio, Jaypirca, Retevmo |
| Menarini Silicon Biosystems, INC. | $112.06 | 2023 | Cellsearch |
| Takeda Pharmaceuticals U.S.A., INC. | $102.35 | 2019-2024 | Alunbrig |
| Glaxosmithkline, LLC. | $100.91 | 2022-2025 | Jemperli, Zejula, Ojjaara |
| Taiho Oncology, INC. | $98.48 | 2020-2025 | |
| Incyte Corporation | $81.89 | 2021 | |
| Immunocore Limited | $78.04 | 2023 | Kimmtrak |
| Coherus Oncology, INC. | $73.76 | 2020-2025 | Loqtorzi, Udenyca |
| Beone Medicines USA, INC. | $63.06 | 2025 | Tevimbra, Brukinsa |
| Eisai INC. | $62.14 | 2019-2025 | |
| Array Biopharma INC | $60.06 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Sobi, INC | $53.14 | 2023-2025 | |
| Iovance Biotherapeutics, INC. | $51.21 | 2025 | Amtagvi |
| Kite Pharma, INC. | $50.39 | 2022-2025 | Yescarta |
| Puma Biotechnology, INC. | $44.88 | 2021-2023 | |
| Eusa Pharma (US) LLC | $41.07 | 2019 | |
| Tersera Therapeutics LLC | $39.32 | 2024 | Zoladex |
| Mirati Therapeutics, INC. | $38.71 | 2023 | Krazati |
| Janssen Scientific Affairs, LLC | $37.61 | 2022 | |
| Dendreon Pharmaceuticals LLC | $35.00 | 2024 | Provenge |
| Novocure INC. | $34.83 | 2020 | |
| Recordati_rare_diseases_inc. | $33.30 | 2025 | Sylvant |
| Pharmacosmos Therapeutics INC. | $25.07 | 2024 | Monoferric |
| Genentech USA, INC. | $24.44 | 2022 | |
| Accord Healthcare, INC. | $22.60 | 2023 | |
| Karyopharm Therapeutics INC. | $21.82 | 2022 | |
| Fresenius Kabi USA, LLC | $17.95 | 2023 | Stimufend |
| Tesaro, INC. | $17.77 | 2019 | |
| Fennec Pharmaceuticals, INC. | $17.53 | 2024 | Pedmark |
| Epizyme, INC. | $17.11 | 2020 | |
| Tempus Ai, INC | $16.66 | 2025 | Xt Cdx |
| Agios Pharmaceuticals, INC. | $16.53 | 2024 | Pyrukynd |
| Seagen INC. | $15.38 | 2019 | |
| Secura Bio, INC. | $14.15 | 2020 | |
| Sirtex Medical INC | $13.65 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.45 | 2019 | |
| Athena Bioscience, LLC | $5.71 | 2023 | Qdolo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pushpendu Banerjee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.